Recombinetics announced a multi-project, collaborative research and development agreement with Mayo Clinic to advance capabilities to bioengineer human stem cells within swine models. The collaboration is focused on utilizing human stem cells to produce human tissue products in a surrogate pig for exo-transplantation back into humans. These regenerative stem cell therapies aim to provide better health outcomes for patients by delaying the need for a transplant and reducing other complications including rejection and related cancers.
The collaboration brings together proprietary technologies including customized biomedical swine from Recombinetics’ regenerative medicine division, Regenevida, and quality control processes and high-quality stem cells from ReGen Theranostics. Project leads are Dr. Timothy Nelson, M.D., Ph.D. from Mayo Clinic and Dan Carlson, Ph.D., Recombinetics’ Senior Vice President of Research and Development.
